Median overall survival of all 211 patients was 49.3 months.
所有211名患者的中位总存活数是49.3个月。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
但中位总生存期，次要观察终点，联合组为20.5个月，而单药治疗组为20.6个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
As noted, however, no significant difference in overall survival was seen between the groups, with a median survival period for each of about 26 months.
然而，正如已经提到的，在各组之间没有看到总体存活率的显著性差异，中值存活期分别为约26个月。
Median survival reflects one time point along the survival curve and does not measure the overall survival benefit.
生存中值反映了生存曲线上的一个时间点，并不能测量总的生存期。
Results: the overall 5-year survival of the patients was 82.0% and the median survival time was 100.0 months.
结果：本组盆腔淋巴结阴性患者的五年总体生存率为82 0 %，中位生存时间10 0 0月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
应用推荐